Education
About Us
Working with TipRanks
Follow Us
Enlivex Therapeutics Ltd (ENLV)
NASDAQ:ENLV
ENLV Stock Chart & Stats
$1.11
-$0.07(-5.60%)
At close: 4:00 PM EST
$1.11
-$0.07(-5.60%)
Day’s Range― - ―
52-Week Range$0.66 - $2.10
Previous CloseN/A
Volume59.48K
Average Volume (3M)182.02K
Market Cap
$263.49M
Enterprise Value$23.48M
Total Cash (Recent Filing)$18.32M
Total Debt (Recent Filing)$701.00K
Price to Earnings (P/E)―
Beta1.02
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding237,381,500
10 Day Avg. Volume216,695
30 Day Avg. Volume182,016
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)1.02
Price to Sales (P/S)0.00
P/FCF Ratio-1.83
Enterprise Value/Market Cap0.09
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-80.42
Enterprise Value/Ebitda-1.72
Forecast
1Y Price Target
$13.00Price Target Upside1071.17% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical ProgressSustained positive six-month Phase IIa data materially de-risks Allocetra’s clinical profile versus short-term signals. Durable efficacy and a favorable safety read support higher probability of advancing into later trials, improve partnerability and underwrite longer-term commercial potential.
Capitalization / RunwayA $212M private placement meaningfully extends operational runway and funds clinical and strategic initiatives. This capital reduces near-term financing urgency, enabling more deliberate trial execution, potential partnering discussions and reduced execution risk over the next several quarters.
Low LeverageVery low reported leverage preserves financial optionality for a pre-revenue biotech. With minimal debt service obligations, management can prioritize R&D spend, pursue collaborations or absorb trial setbacks without immediate solvency pressure, supporting resilient balance sheet strategy.
Bears Say
Pre-Commercial Business ModelAbsence of product revenue makes Enlivex entirely dependent on financing events until approval/commercialization. That structural revenue gap lengthens payback timelines, increases reliance on external capital and amplifies binary program risk inherent to clinical-stage biotech development.
Persistent Cash BurnConsistent negative operating and free cash flow indicates ongoing cash burn tied to R&D and operations. This structural cash deficit necessitates periodic capital raises, diluting shareholders and creating execution uncertainty if market conditions or financing capacity tighten over the medium term.
Digital-Asset Treasury RiskShifting material treasury exposure into crypto assets introduces persistent balance-sheet volatility and regulatory complexity. This structural change can increase earnings and asset valuation variability, distract management from core drug development, and complicate long-term capital allocation decisions.
Enlivex News
ENLV FAQ
What was Enlivex Therapeutics Ltd’s price range in the past 12 months?
Enlivex Therapeutics Ltd lowest stock price was $0.66 and its highest was $2.10 in the past 12 months.
What is Enlivex Therapeutics Ltd’s market cap?
Enlivex Therapeutics Ltd’s market cap is $263.49M.
When is Enlivex Therapeutics Ltd’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Enlivex Therapeutics Ltd’s earnings last quarter?
Currently, no data Available
Is Enlivex Therapeutics Ltd overvalued?
According to Wall Street analysts Enlivex Therapeutics Ltd’s price is currently Undervalued.
Does Enlivex Therapeutics Ltd pay dividends?
Enlivex Therapeutics Ltd does not currently pay dividends.
What is Enlivex Therapeutics Ltd’s EPS estimate?
Enlivex Therapeutics Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Enlivex Therapeutics Ltd have?
Enlivex Therapeutics Ltd has 237,381,500 shares outstanding.
What happened to Enlivex Therapeutics Ltd’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Enlivex Therapeutics Ltd?
Currently, no hedge funds are holding shares in ENLV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Enlivex Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$13.00 (1071.17% Upside)
$13.00 (1071.17% Upside)
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.7%
Last 30 Days ▲ 4.0%
Last 30 Days ▲ 4.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-34.96%
12-Months-Change
Fundamentals
Return on Equity
-57.64%
Trailing 12-Months
Asset Growth
-29.16%
Trailing 12-Months
Company Description
Enlivex Therapeutics Ltd
Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Nes Ziona, Israel.
ENLV Stock 12 Month Forecast
Average Price Target
$13.00
▲(1071.17% Upside)
Technical Analysis
Ownership Overview
―
Insiders
<0.01% Mutual Funds
0.13% Other Institutional Investors
99.61% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---